In a rodent model of DM and diabetic nephropathy, MSC treatment ameliorated diabetic nephropathy via inhibition of MCP-1 expression by secreting HCP, thus reducing macrophage infiltration and down-regulating Il-1β, IL-6, and TNF-α expression in the renal tissue of diabetic rates (116). Here, CCL2 is linked to diabetic kidney disease.